C3a 70-77 (Complement 3a (70-77))
(Synonyms: 人永生化肝细胞,Complement 3a (70-77)) 目录号 : GC31928C3a 70-77 (Complement 3a (70-77)) 是一种对应于 C3a 的 COOH 末端的八肽,具有 C3a 的特异性和 1% 至 2% 的生物活性。
Cas No.:63555-63-5
Sample solution is provided at 25 µL, 10mM.
C3a (70-77) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.
The direct interaction of C3a(70-77) with human mononuclear leukocytes in culture results in a concentrationdependent inhibition of the generation of LIF evoked by mitogens and by the antigen SK-SD. The extent of suppression of LIF generation by C3a(70-77) is significant at concentrations of 10-7 M or higher and exceeds 75% at 10-6 M, irrespective of the stimulus[1]. C3a (70-77), an octapeptide corresponding to the COOH terminus of human C3a, exhibits the specificity and biologic activities of C3a. Although lacking 69 residues at the NH2 terminus, it maintains 1 to 2% of the activity of natural human C3a. C3a (70-77), Ala-Ser-HisLeu-Gly-Leu-Ala-Arg, induces histamine release and degranulation of rat mast cells, promotes contraction of guinea pig ileal tissue, and enhances vascular permeability in human skin. C3a (70-77) selectively desensitizes ileal smooth muscle to C3a but not to human C5a, a related anaphylatoxin. Conversely, C3a-(70-77) is unable to contract ileal smooth muscle pretreated with natural C3a. This cross-desensitization indicates a specific interaction of C3a (70-77) with cellular C3a binding sites[2].
[1]. Payan DG, et al. Modulation of human lymphocyte function by C3a and C3a(70-77). J Exp Med. 1982 Sep 1;156(3):756-65. [2]. Caporale LH, et al. The active site of C3a anaphylatoxin. J Biol Chem. 1980 Nov 25;255(22):10758-63.
Kinase experiment: | 2×105 mononuelear leukocytes in 0.2 mL of M199-HPS containing 15% (vol/vol) AB-positive serum are added to each well of microtiter plates without or with 10 μg/mL of Con A, PHA, or SK-SD and incubated at 37°C in 5% CO2:95% air. C3a or C3a(70-77) is introduced into some suspensions at the same time as the stimulus or buffer. After 3 d for the mitogen-stimulated cultures and 5 d for the SK-SD-stimulated cultures, 1 μCi of [3H]thymidine is added to each well. After an additional 16 h at 37°C, the uptake of [3H]thymidine is analyzed by aspirating the contents of each well with a Mash II harvester that collected and ished the leukocytes on glass fiber filters. The radioactivity in each filter is quantified, and the results for quadruplicate chambers are expressed as mean cpm+SEM[1]. |
References: [1]. Payan DG, et al. Modulation of human lymphocyte function by C3a and C3a(70-77). J Exp Med. 1982 Sep 1;156(3):756-65. |
Cas No. | 63555-63-5 | SDF | |
别名 | 人永生化肝细胞,Complement 3a (70-77) | ||
Canonical SMILES | Ala-Ser-His-Leu-Gly-Leu-Ala-Arg | ||
分子式 | C35H61N13O10 | 分子量 | 823.94 |
溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.2137 mL | 6.0684 mL | 12.1368 mL |
5 mM | 0.2427 mL | 1.2137 mL | 2.4274 mL |
10 mM | 0.1214 mL | 0.6068 mL | 1.2137 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet